

## Asana BioSciences, LLC

*For Immediate Release*

### **Asana BioSciences Appoints Dr. Kapil Dhingra to its Oncology Scientific Advisory Board**

**Bridgewater, N. J. (USA), January 4, 2016** – Asana BioSciences, LLC today announced that Kapil Dhingra, M.D., has been appointed to its oncology scientific advisory board (SAB). Dr. Dhingra is the former head of Roche Oncology Clinical Development and the founder of KAPital Consulting, LLC.

“We welcome Dr. Dhingra to our oncology scientific advisory board. His expertise, proven track record and strategic insights will be great assets to Asana. I look forward to working closely with him and other SAB members in advancing our robust and differentiated oncology pipeline further into clinical development,” said Dr. Sandeep Gupta, founder, president and CEO of Asana Biosciences.

“I am pleased to join the Asana SAB at this important inflection point in the evolution of the company” said Dr. Dhingra. “The Asana team has established a unique business model that allows the pursuit of numerous important and differentiated assets, in parallel, and in an accelerated and capital-efficient manner. I look forward to working the management team and fellow SAB members to help realize the promise of these new medicines.”

Dr. Dhingra is an accomplished medical oncologist and physician-scientist. He received his medical training at the All India Institute of Medical Sciences, New Delhi, India, followed by an internal medicine residency at Lincoln Medical Center, New York and a hematology-oncology fellowship at Emory University in Atlanta, Georgia. In 1989, he joined the faculty of M.D. Anderson Cancer Center in Houston, Texas, where he pursued laboratory and clinical cancer research, in addition to his direct patient care responsibilities. Dr. Dhingra later joined Eli Lilly and Company as clinical research physician. From 1999 to 2008, he worked at Hoffmann-La Roche, where he served in roles of increasing responsibility, most recently as vice president, head of the Oncology Disease Biology Leadership team and head of Oncology Clinical Development. He serves on scientific/clinical advisory boards as well as board of directors of a number of companies and non-profit organizations. He presently serves on the boards of Exosome Diagnostics as chairman of the board, Advanced Accelerator Applications (NASDAQ-listed), Five Prime (NASDAQ-listed) and Autolus in London, U.K. He previously served on the boards of Biovex, Micromet, YM Biosciences, Algeta and Epitherapeutics, which were all acquired by major pharmaceutical companies, such as Amgen, Bayer and Gilead. He has authored or co-authored more than 100 scientific publications and abstracts.

Dr. Dhingra joins an illustrious group of scientific advisors to Asana such as Dr. Keith Flaherty and Dr. Jeffery Engelman from Massachusetts General Hospital/Harvard Medical School, Boston; Dr. Anas Younes and Dr. David Solit from Memorial Sloan Kettering Cancer Center, New York; Dr. Robert Dreicer from the University of Virginia; Dr. Anil Rustgi from the University of Pennsylvania and Dr. Anthony Tolcher of START, San Antonio, Texas.

#### **About Asana BioSciences, LLC**

Asana BioSciences, LLC, an independent member of the Amneal Alliance of Companies, is a research and development company based in Bridgewater, New Jersey, specializing in the discovery and development of new chemical and biological entities. Asana's portfolio consists of multiple early-stage drug discovery and development candidates in a variety of therapeutic areas, including oncology, pain and inflammation, among others. Asana recently presented preclinical and early clinical data from its ongoing Phase I/II trial of ASN002, the company's potent, oral inhibitor of spleen tyrosine kinase (SYK) and Janus kinase family (JAK), at the 57th American Society of Hematology (ASH) Annual Meeting and Exposition; and preclinical data for ASN003, a novel potent, dual inhibitor of B-Raf and PI3 Kinase pathways, at the EORTC-NCI-AACR meeting in Boston. Asana's other lead molecule ASN001 (CYP17 inhibitor for prostate cancer) is currently in Phase I/II clinical studies in the U.S. Several other molecules in Asana's portfolio are currently in the late stages of preclinical development.

[www.asanabiosciences.com](http://www.asanabiosciences.com)

#### **CONTACT:**

Roger Smith, Ph.D.

Vice President

T: 908-698-0839

[roger.smith@asanabio.com](mailto:roger.smith@asanabio.com)

[www.asanabiosciences.com](http://www.asanabiosciences.com)